EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

被引：2

作者：

Mease, P. J. ^{[1
,2
]}

Deodhar, A. ^{[3
]}

Van der Heijde, D. ^{[4
]}

Behrens, F. ^{[5
]}

Kivitz, A. ^{[6
]}

Lehman, T. ^{[7
]}

Wei, L. ^{[8
]}

Nys, M. ^{[9
]}

Banerjee, S. ^{[10
]}

Nowak, M. ^{[11
]}

机构：

[1] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA

[3] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA

[4] Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands

[5] Goethe Univ, Translat Med & Pharmacol ITMP, CIRI Rheumatol & Fraunhofer Inst, Frankfurt, Germany

[6] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA

[7] Bristol Myers Squibb, Rheumatol, Princeton, NJ USA

[8] Bristol Myers Squibb, Med Immunol, Princeton, NJ USA

[9] Bristol Myers Squibb, GBS Biostat, Braine Lalleud, Belgium

[10] Bristol Myers Squibb, Rheumatol & Dermatol, Princeton, NJ USA

[11] Bristol Myers Squibb, Clin R&D, Princeton, NJ USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷

关键词：

D O I：

10.1136/annrheumdis-2021-eular.2653

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0227

引用

页码：137 / 138

页数：2

共 50 条

[41] Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis - A multinational, double-blind, randomized, placebo-controlled clinical trial
Kaltwasser, JP
Nash, P
Gladman, D
Rosen, CF
Behrens, F
Jones, P
Wollenhaupt, J
Falk, FG
Mease, P
ARTHRITIS AND RHEUMATISM, 2004, 50 (06): : 1939 - 1950
[42] SULFASALAZINE THERAPY FOR PSORIATIC-ARTHRITIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
GUPTA, AK
GROBER, JS
HAMILTON, TA
ELLIS, CN
SIEGEL, MT
VOORHEES, JJ
MCCUNE, WJ
JOURNAL OF RHEUMATOLOGY, 1995, 22 (05) : 894 - 898
[43] Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
Butchart, Joseph
Brook, Laura
Hopkins, Vivienne
Teeling, Jessica
Puentener, Ursula
Culliford, David
Sharples, Richard
Sharif, Saif
McFarlane, Brady
Raybould, Rachel
Thomas, Rhodri
Passmore, Peter
Perry, V. Hugh
Holmes, Clive
NEUROLOGY, 2015, 84 (21) : 2161 - 2168
[44] ETANERCEPT IN ALZHEIMER DISEASE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 2 TRIAL
Tufan, Ayse N.
Tufan, Fatih
NEUROLOGY, 2015, 85 (23) : 2083 - 2084
[45] Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial
Imafuku, Shinichi
Tada, Yayoi
Hippeli, Lauren
Banerjee, Subhashis
Morita, Akimichi
Ohtsuki, Mamitaro
JOURNAL OF DERMATOLOGY, 2023, 50 (05): : 588 - 595
[46] A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia
Kuriakose, Moni Abraham
Ramdas, Kunnambath
Dey, Bindu
Iyer, Subramanya
Rajan, Gunaseelan
Elango, Kalavathy K.
Suresh, Amritha
Ravindran, Divya
Kumar, Rajneesh R.
Prathiba, R.
Ramachandran, Surya
Kumar, Nisha Asok
Thomas, Gigi
Somanathan, Thara
Ravindran, Hiran K.
Ranganathan, Kannan
Katakam, Sudhakar Babu
Parashuram, Shivashankar
Jayaprakash, Vijayvel
Pillai, M. Radhakrishna
CANCER PREVENTION RESEARCH, 2016, 9 (08) : 683 - 691
[47] SAFETY AND EFFICACY OF SBI-087 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Damjanov, N.
Tlustochowicz, M.
Aelion, J.
Dimic, A.
Greenwald, M.
Diehl, A.
Bhattacharya, I.
Menon, S.
Gourley, I.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 60 - 61
[48] Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters - Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis
Fleischmann, Roy
Thaci, Diamant
Gooderham, Melinda
Strober, Bruce
Korman, Neil J.
Banerjee, Subhashis
Lehman, Tom
Nowak, Miroslawa
Sreih, Antoine
Morita, Akimichi
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4227 - 4228
[49] Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Mease, Philip
Coates, Laura C.
Helliwell, Philip S.
Stanislavchuk, Mykola
Rychlewska-Hanczewska, Anna
Dudek, Anna
Abi-Saab, Walid
Tasset, Chantal
Meuleners, Luc
Harrison, Pille
Besuyen, Robin
Van der Aa, Annegret
Mozaffarian, Neelufar
Greer, Joy M.
Kunder, Rebecca
Van den Bosch, Filip
Gladman, Dafna D.
LANCET, 2018, 392 (10162): : 2367 - 2377
[50] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CHIGLITAZAR IN NASH PATIENTS
You, Hong
Sun, Yameng
Wu, Cuisong
Xin, Guijie
Zhong, Bihui
Wu, Xiaofeng
Liu, Yali
Shi, Junping
Zhang, Qin
Zhao, Yingren
Gao, Yufeng
Xin, Yongning
Zhu, Yueyong
Wu, Lixian
Mao, Xiaorong
Du, Jian
Shang, Jia
Sun, Weiwei
Xu, Jie
Yu, Zujiang
Nan, Yuemin
Sheng, Huiping
Li, Yue
Rao, Huiying
Yu, Chaohui
Wu, Xiaoning
Tong, Xiaofei
HEPATOLOGY, 2024, 80 : S1969 - S1970

← 1 2 3 4 5 →